Evidence map›Paper›PMID 28091975›Full record

ArticleWiener medizinische Wochenschrift (1946)2019

Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies.

Andrew Kwong, Martina Sanlorenzo, Klemens Rappersberger, Igor Vujic

Abstract read
PubMed Publisher
In one paragraph

Article in Wiener medizinische Wochenschrift (1946), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Donor-Transmitted Melanoma: Is It Still Bothering Us?Current treatment options in oncology · 2020
    Review
  3. Imidazo[1,2-Molecules (Basel, Switzerland) · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Andrew KwongKeck School of Medicine of USC (University of Southern California), Los Angeles, CA, USA.
Martina SanlorenzoDepartment of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy.
Klemens RappersbergerRudolfstiftung Hospital, Academic Teaching Hospital, Medical University Vienna, Juchgasse 25, Vienna, 1030, Austria.
Igor VujicRudolfstiftung Hospital, Academic Teaching Hospital, Medical University Vienna, Juchgasse 25, Vienna, 1030, Austria. igor.vujic.md@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early stage melanomas can achieve remarkable outcomes with surgery alone, but stage IV metastatic melanoma requires significant intervention and has poor outcomes. Here we present evidence on the latest advances in melanoma treatment, discuss the scientific concepts behind new therapies, and analyze the potential of future treatment combinations.

Indexed as

ImmunotherapyMelanomaMolecular Targeted TherapyCombined Modality TherapyHumansEfficacyImmunotherapyMalignant melanomaTargeted molecular therapyTherapy

Identifiers

PMID28091975

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.